

Date: 12<sup>th</sup> July, 2018

To,  
The Manager,  
Department of Corporate Services,  
BSE Limited  
P. J. Tower, Dalal Street,  
Fort, Mumbai – 400 001

Dear Sir/Madam,

**Sub: Alembic Pharmaceuticals Limited receives USFDA Tentative Approval for Ticagrelor Tablets, 90 mg.**

With reference to the captioned subject, this is to inform the exchange that the Company has received US Food & Drug Administration (USFDA) Tentative Approval for Ticagrelor Tablets, 90 mg. Please find enclosed herewith our press release.

We request you to kindly take the same on record.

Thanking you,

Yours faithfully,  
**For Alembic Pharmaceuticals Limited**

**Charandeep Singh Saluja**  
**Company Secretary**

Encl.: A/a.

**PRESS RELEASE**

12<sup>th</sup> July, 2018, Vadodara, India

**Alembic Pharmaceuticals receives USFDA Tentative Approval for Ticagrelor Tablets, 90 mg.**

Alembic Pharmaceuticals Limited today announced that the company has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Ticagrelor Tablets, 90 mg. The tentatively approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Brilinta Tablets, 90 mg, of Astrazeneca Pharmaceuticals LP. Ticagrelor tablets are indicated to reduce the rate of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome (ACS) or a history of myocardial infarction (MI).

Ticagrelor Tablets, 90 mg have an estimated market size of US\$ 625 million for twelve months ending December 2017 according to IQVIA.

Alembic now has a total of 75 ANDA approvals (65 final approvals and 10 tentative approvals) from USFDA.

**About Alembic Pharmaceuticals Limited**

Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the USFDA. Alembic is one of the leaders in branded generics in India. Alembic's brands, marketed through a marketing team of over 5000 are well recognized by doctors and patients.

Information about the company can be found at <http://www.alembicpharmaceuticals.com/>; (Reuters: ALEM.NS) (Bloomberg: ALPM) (NSE: APLLTD) (BSE: 533573)

For more information contact:

Ajay Kumar Desai	Mitanshu Shah
Phone: +91 22 - 306 11681	Phone: +91 265 - 3007630
Email: <a href="mailto:ajay.desai@alembic.co.in">ajay.desai@alembic.co.in</a>	Email: <a href="mailto:mitanshu.shah@alembic.co.in">mitanshu.shah@alembic.co.in</a>



**ALEMBIC PHARMACEUTICALS LIMITED**

REGD. OFFICE : ALEMBIC ROAD, VADODARA - 390 003. • TEL : (0265) 2280550, 2280880 • FAX : (0265) 2281229  
website : [www.alembicpharmaceuticals.com](http://www.alembicpharmaceuticals.com) • E-mail : [alembic@alembic.co.in](mailto:alembic@alembic.co.in) • CIN : L24230GJ2010PLC061123